Articles
Alemtuzumab as First-line Treatment for Progressive B-cell Chronic Lymphocytic Leukaemia
This latter observation is largely due to the ability to successfully re-treat relapsed patients. However, patients who become refractory to...
Association between thymoma and persistent hypothermia: a case report
Introduction The thymus is a small anterosuperior mediastinal organ involved in the processing and maturation of T lymphocytes. The thymus gland...
Chemo-immunotherapy - The Role of Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukaemia
Combination Chemotherapy with Purine Analogues Fludarabine has been evaluated in a variety of combination regimens. One of the most promising and...
IRIS at Five Years Still Changing the Face of Long-term Chronic Myeloid Leukemia Therapy
The standard therapeutic options that were available before the imatinib era were recombinant interferon-alpha, chemotherapy with hydroxyurea,...
Long-term Chronic Myeloid Leukaemia Therapy
Clinically, CML progresses through three distinct phases of increasing refractoriness to therapy: chronic phase (median duration three to four years;...
Molecular Diagnostics and Risk-stratification in Chronic Lymphocytic Leukaemia
Some patients are primary refractory or develop treatment resistance during the course of the disease, a situation with a particularly poor prognosis...
New Developments in the Treatment of Chronic Lymphocytic Leukaemia
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in adults. It is caused by antigen-experienced B lymphocytes that either do...
Nilotinib in Chronic-phase Chronic Myeloid Leukemia
CML is a monoclonal stem cell disorder accounting for approximately 20% of adult leukemias.1 The median age at first diagnosis is 60 years and the...
Treatment Strategies for Chronic Lymphocytic Leukaemia
In approximately 5% of patients, CLL can undergo transformation to a more aggressive lymphoid neoplasm, most commonly a diffuse large B-cell lymphoma...
